by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pharma loves success stories. They fill conferences, case studies, and LinkedIn posts. Yet the most useful lessons often come from the launches that quietly underperformed — the ones no one wants to talk about. Having seen more than a few, I’ve noticed recurring...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pricing strategies get plenty of attention in pharma. Teams hold workshops, hire consultants, and produce slide decks that look increasingly complex but say roughly the same thing. Yet, a pricing strategy on its own achieves little. Without genuine payer...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Market access is one of those phrases that looks perfect on a slide deck. It sounds strategic, sophisticated, and forward-thinking. Yet, when you look closely at underperforming launches, one pattern keeps repeating: access planning started too late. Everyone agrees...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
After two decades in pharma and market access, I’ve seen launches succeed spectacularly, stumble unexpectedly, and sometimes collapse entirely. Through all of it, one lesson stands out above the rest: start with the system, not the science. Science dazzles. It wins...
by Tony Akiwumi | Nov 5, 2025 | Pharma / Market Access
Pharma often treats access as a regulatory hurdle: tick the box, submit the dossier, wait for approval, and hope payers follow. Tech and consumer industries, by contrast, treat access as the game itself. That distinction is why there’s so much for pharma to learn....
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Pharma teams spend months crafting “value stories.” They’re sleek, glossy, and full of optimism. They highlight innovation, unmet need, and potential impact. And yet, when these stories reach payers, they often fall flat. The question is: why? The problem is simple....
